This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Legrier, M.-E. Articles by McDaid, H. M. Search for Related Content PubMed PubMed Citation Articles by Legrier, M.-E. Articles by McDaid, H. M.

Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression

Departments of ¹ Molecular Pharmacology and ² Medicine, Albert Einstein College of Medicine, and ³ Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, New York

Requests for reprints: Hayley McDaid, Department of Molecular Pharmacology, Golding 201, 1300 Morris Park Avenue, Albert Einstein College of Medicine, Bronx, NY 10461. Phone: 718-430-2192; Fax: 718-430-8959; E-mail: mcdaid{at}aecom.yu.edu.

Lung cancer is a genetically heterogeneous disease characterized by the acquisition of somatic mutations in numerous protein kinases, including components of the rat sarcoma viral oncogene homolog (RAS) and AKT signaling cascades. These pathways intersect at various points, rendering this network highly redundant and suggesting that combined mitogen-activated protein/extracellular signal-regulated kinase (MEK) and mammalian target of rapamycin (mTOR) inhibition may be a promising drug combination that can overcome its intrinsic plasticity. The MEK inhibitors, CI-1040 or PD0325901, in combination with the mTOR inhibitor, rapamycin, or its analogue AP23573, exhibited dose-dependent synergism in human lung cancer cell lines that was associated with suppression of proliferation rather than enhancement of cell death. Concurrent suppression of MEK and mTOR inhibited ribosomal biogenesis by 40% within 24 h and was associated with a decreased polysome/monosome ratio that is indicative of reduced protein translation efficiency. Furthermore, the combination of PD0325901 and rapamycin was significantly superior to either drug alone or PD0325901 at the maximum tolerated dose in nude mice bearing human lung tumor xenografts or heterotransplants. Except for a PTEN mutant, all tumor models had sustained tumor regressions and minimal toxicity. These data (a) provide evidence that both pathways converge on factors that regulate translation initiation and (b) support therapeutic strategies in lung cancer that simultaneously suppress the RAS and AKT signaling network. [Cancer Res 2007;67(23):11300–8]

This article has been cited by other articles:

				C. Sessa, D. Tosi, L. Vigano, J. Albanell, D. Hess, M. Maur, S. Cresta, A. Locatelli, R. Angst, F. Rojo, et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel Ann. Onc., November 9, 2009; (2009) mdp504v1. [Abstract] [Full Text] [PDF]

				N. Jin, T. Jiang, D. M. Rosen, B. D. Nelkin, and D. W. Ball Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 4107 - 4112. [Abstract] [Full Text] [PDF]

				P. A. OLIVEIRA, R. ARANTES-RODRIGUES, C. SOUSA-DINIZ, A. COLACO, L. LOURENCO, L. FELIPE. DE LA CRUZ P., V. M. DA SILVA, J. AFONSO, C. LOPES, and L. SANTOS The Effects of Sirolimus on Urothelial Lesions Chemically Induced in ICR Mice by BBN Anticancer Res, August 1, 2009; 29(8): 3221 - 3226. [Abstract] [Full Text] [PDF]

				B. N. Rexer, R. Ghosh, and C. L. Arteaga Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers Clin. Cancer Res., July 15, 2009; 15(14): 4518 - 4520. [Abstract] [Full Text] [PDF]

				S. Paternot and P. P. Roger Combined Inhibition of MEK and Mammalian Target of Rapamycin Abolishes Phosphorylation of Cyclin-Dependent Kinase 4 in Glioblastoma Cell Lines and Prevents Their Proliferation Cancer Res., June 1, 2009; 69(11): 4577 - 4581. [Abstract] [Full Text] [PDF]

				K. E. O'Reilly, M. Warycha, M. A. Davies, V. Rodrik, X. K. Zhou, H. Yee, D. Polsky, A. C. Pavlick, N. Rosen, N. Bhardwaj, et al. Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma Clin. Cancer Res., April 15, 2009; 15(8): 2872 - 2878. [Abstract] [Full Text] [PDF]

				A. M. Puzio-Kuter, M. Castillo-Martin, C. W. Kinkade, X. Wang, T. H. Shen, T. Matos, M. M. Shen, C. Cordon-Cardo, and C. Abate-Shen Inactivation of p53 and Pten promotes invasive bladder cancer Genes & Dev., March 15, 2009; 23(6): 675 - 680. [Abstract] [Full Text] [PDF]